mitiglinide

Mitiglinide is a rapid-onset, short-duration oral antidiabetic drug of the meglitinide (glinide) class, used for the treatment of type 2 diabetes mellitus. It acts as an insulin secretagogue by stimulating pancreatic β-cells to release insulin. The mechanism involves closing ATP-sensitive potassium channels (KATP channels), specifically by binding to the sulfonylurea receptor 1 (SUR1/ABCC8) subunit on pancreatic β-cells, leading to membrane depolarization and subsequent insulin secretion. Mitiglinide is structurally a derivative of benzylsuccinic acid and is classified as a small molecule hypoglycemic agent[1][4][5][6][8]. It has a rapid onset and short duration of action, targeting postprandial hyperglycemia[4]. Developed originally in Japan, it is marketed under several brand names including Glufast.

Brand names

GlufastGlinsunaKuai ruo tuo

Other names

mitiglinida2-benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionatecalcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydratemiti-glinidemitiglinidum